ELIQUIS TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

APIXABAN

Предлага се от:

BRISTOL-MYERS SQUIBB CANADA

АТС код:

B01AF02

INN (Международно Name):

APIXABAN

дозиране:

2.5MG

Лекарствена форма:

TABLET

Композиция:

APIXABAN 2.5MG

Начин на приложение:

ORAL

Броя в опаковка:

10/20/60/100

Вид предписание :

Prescription

Терапевтична област:

Direct Factor Xa Inhibitors

Каталог на резюме:

Active ingredient group (AIG) number: 0153051001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2011-12-16

Данни за продукта

_Pr_
_ELIQUIS (apixaban) Product Monograph _
_Page 1 of 83_
PRODUCT MONOGRAPH
Pr
ELIQUIS
®
apixaban tablets
2.5 mg and 5 mg
Anticoagulant
Pfizer Canada ULC
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Bristol-Myers Squibb Canada Co.
Montreal, Canada H4S 0A4
www.bmscanada.ca
Date of Initial Approval:
13 December 2011
Date of Revision:
07 October 2019
Registered trademark of Bristol-Myers Squibb Company used under
license by Bristol-Myers
Squibb Canada Co.
Submission Control No: 229267
_Pr_
_ELIQUIS (apixaban) Product Monograph _
_Page 2 of 83_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
10
DOSAGE AND ADMINISTRATION
.............................................................................
26
OVERDOSAGE
................................................................................................................
33
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 34
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
39
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 39
PART II: SCIENTIFIC INFORMATION
..............................................................................
41
PHARMACEUTICAL INFORMATION
.........................................................................
41
CLINICAL TRIALS
........................................................